Sustained EKR inhibition by EGFR targeting therapies is a predictive factor for synergistic cytotoxicity with PDT as neoadjuvant therapy

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 3, 2013, Pages 2659-2670

  Weyergang, Anette ^a   Selbo, Pål K ^a,b   Berg, Kristian ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b PCI Biotech AS   (Norway)

Author keywords

Cetuximab; epidermal growth factor receptor (EGFR); Erlotinib; extracellular signal regulated kinase (ERK); Photodynamic; Tyrphostin AG1478

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CETUXIMAB; ERLOTINIB; TETRAPHENYLPORPHINESULFONIC ACID; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOTOSENSITIZING AGENT; PORPHYRIN; QUINAZOLINE DERIVATIVE; TETRAPHENYLPORPHINE; TYRPHOSTIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CELL COUNT; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA; WESTERN BLOTTING; ADJUVANT THERAPY; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOTOCHEMOTHERAPY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL COUNT; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TYRPHOSTINS;

MLCS; MLOWN;

EID: 84873575601     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.11.010     Document Type: Article

References (50)

1. J.E. Dancey, and H.X. Chen Strategies for optimizing combinations of molecularly targeted anticancer agents Nat. Rev. Drug Discov. 5 8 2006 Aug 649 659
2. F. Ye, Q. Gao, and M.J. Cai Therapeutic targeting of EGFR in malignant gliomas Expert Opin. Ther. Targets 14 3 2010 Mar 303 316
3. M. Sundvall, A. Karrila, J. Nordberg, R. Grenman, and K. Elenius EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma Expert Opin. Emerg. Drugs 15 2 2010 Jun 185 201
4. F. Ciardiello, and G. Tortora EGFR antagonists in cancer treatment N. Engl. J. Med. 358 11 2008 Mar 13 1160 1174
5. B. You, and E.X. Chen Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of Cetuximab and Panitumumab J. Clin. Pharmacol. 52 2 2012 Feb 128 155
6. A.B. Heimberger, C.A. Learn, G.E. Archer, R.E. McLendon, T.A. Chewning, and F.L. Tuck Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa) Clin. Cancer 8 11 2002 Nov 3496 3502
7. M.Y. Khalil, J.R. Grandis, and D.M. Shin Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer Expert Rev. Anticancer Ther. 3 3 2003 Jun 367 380
8. P.A. Janne, N. Gray, and J. Settleman Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat. Rev. Drug Discov. 8 9 2009 Sep 709 723
9. T.J. Dougherty, C.J. Gomer, B.W. Henderson, G. Jori, D. Kessel, and M. Korbelik Photodynamic therapy J. Natl. Cancer Inst. 90 12 1998 Jun 17 889 905
10. D.E. Dolmans, D. Fukumura, and R.K. Jain Photodynamic therapy for cancer Nat. Rev. Cancer 3 5 2003 May 380 387
11. P. Agostinis, K. Berg, K.A. Cengel, T.H. Foster, A.W. Girotti, and S.O. Gollnick Photodynamic therapy of cancer: an update CA Cancer J. Clin. 61 4 2011 May 26 250 281
12. A. Ferrario, and C.J. Gomer Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model J. Environ. Pathol. Toxicol. Oncol. 25 1-2 2006 251 259
13. A. Ferrario, A.M. Fisher, N. Rucker, and C.J. Gomer Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors Cancer Res. 65 20 2005 Oct 15 9473 9478
14. W. Liu, M.R. Baer, M.J. Bowman, P. Pera, X. Zheng, and J. Morgan The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2 Clin. Cancer Res. 13 8 2007 Apr 15 2463 2470
15. S.B. Brown, E.A. Brown, and I. Walker The present and future role of photodynamic therapy in cancer treatment Lancet Oncol. 5 8 2004 Aug 497 508
16. A. Weyergang, O. Kaalhus, and K. Berg Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478 Photochem. Photobiol. Sci. 7 9 2008 Sep 1032 1040
17. M.G. del Carmen, I. Rizvi, Y. Chang, A.C. Moor, E. Oliva, and M. Sherwood Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo J. Natl. Cancer Inst. 97 20 2005 Oct 1516 1524
18. A.G. Ellis, M.M. Doherty, F. Walker, J. Weinstock, M. Nerrie, and A. Vitali Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase Biochem. Pharmacol. 71 10 2006 May 14 1422 1434
19. A. Weyergang, O. Kaalhus, and K. Berg Photodynamic therapy with an endocytically located photosensitizer cause a rapid activation of the mitogen-activated protein kinases extracellular signal-regulated kinase, p38 and c-Jun NH2 terminal kinase with opposing effects on cell survival Mol. Cancer Ther. 7 6 2008 Jun 1740 1750
20. P.K. Selbo, O. Kaalhus, G. Sivam, and K. Berg 5-Aminolevulinic acid-based photochemical internalization of the immunotoxin MOC31-gelonin generates synergistic cytotoxic effects in vitro Photochem. Photobiol. 74 2 2001 Aug 303 310
21. G.G. Steel, and M.J. Peckham Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int. J. Radiat. Oncol. Biol. Phys. 5 1 1979 Jan 85 91
22. A. Weyergang, P.K. Selbo, and K. Berg Y1068 phosphorylation is the most sensitive target of disulfonated tetraphenylporphyrin-based photodynamic therapy on epidermal growth factor receptor Biochem. Pharmacol. 74 2 2007 Jul 15 226 235
23. D.D. Meira, I. Nobrega, V.H. de Almeida, J.S. Mororo, A.M. Cardoso, and R.L. Silva Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway Eur. J. Cancer 45 7 2009 May 1265 1273
24. R.B. Luwor, Y. Lu, X. Li, J. Mendelsohn, and Z. Fan The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression Oncogene 24 27 2005 Jun 23 4433 4441
25. Y.N. Kim, P. Dam, and P.J. Bertics Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation Exp. Cell Res. 280 1 2002 Oct 15 134 147
26. L. Stryer Biochemistry 3 ed. 1975 W.H. Freeman and Company New York
27. W.A. Denny Irreversible inhibitors of the erbB family of protein tyrosine kinases Pharmacol. Ther. 93 2-3 2002 Feb 253 261
28. H.K. Gan, F. Walker, A.W. Burgess, A. Rigopoulos, A.M. Scott, and T.G. Johns The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806 J. Biol. Chem. 282 5 2007 Feb 2 2840 2850
29. P. Matar, F. Rojo, R. Cassia, G. Moreno-Bueno, C.S. Di, and J. Tabernero Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin. Cancer Res. 10 19 2004 Oct 1 6487 6501
30. T. Yoshida, I. Okamoto, T. Okabe, T. Iwasa, T. Satoh, and K. Nishio Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk Int. J. Cancer 122 7 2008 Apr 1 1530 1538
31. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 4 2005 Apr 301 311
32. M. Perez-Torres, M. Guix, A. Gonzalez, and C.L. Arteaga Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations J. Biol. Chem. 281 52 2006 Dec 29 40183 40192
33. E. Carrasco-Garcia, M. Saceda, S. Grasso, L. Rocamora-Reverte, M. Conde, and A. Gomez-Martinez Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines Exp. Cell Res. 317 10 2011 Jun 10 1476 1489
34. S.G. Kim, J.W. Hong, S.H. Boo, M.G. Kim, K.D. Lee, and J.C. Ahn Combination treatment of Cetuximab and photodynamic therapy in SNU-1041 squamous cancer cell line Oncol. Rep. 22 4 2009 Oct 701 708
35. M. Naramura, S.D. Gillies, J. Mendelsohn, R.A. Reisfeld, and B.M. Mueller Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma Cancer Immunol. Immunother. 37 5 1993 Oct 343 349
36. J. Kurai, H. Chikumi, K. Hashimoto, K. Yamaguchi, A. Yamasaki, and T. Sako Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines Clin. Cancer Res. 13 5 2007 Mar 1 1552 1561
37. J.M. Roda, T. Joshi, J.P. Butchar, J.W. McAlees, A. Lehman, and S. Tridandapani The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines Clin. Cancer Res. 13 21 2007 Nov 1 6419 6428
38. R. Bhuvaneswari, Y.Y. Gan, K.C. Soo, and M. Olivo Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response Mol. Cancer 8 Nov 2 2009 94
39. L. Xue, J. He, and N.L. Oleinick Promotion of photodynamic therapy-induced apoptosis by stress kinases Cell Death Differ. 6 9 1999 Sep 855 864
40. Z. Tong, G. Singh, and A.J. Rainbow Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy Cancer Res. 62 19 2002 Oct 1 5528 5535
41. N.S. Trivedi, H.W. Wang, A.L. Nieminen, N.L. Oleinick, and J.A. Izatt Quantitative analysis of Pc 4 localization in mouse lymphoma (LY-R) cells via double-label confocal fluorescence microscopy Photochem. Photobiol. 71 5 2000 May 634 639
42. Y.J. Hsieh, C.C. Wu, C.J. Chang, and J.S. Yu Subcellular localization of Photofrin determines the death phenotype of human epidermoid carcinoma A431 cells triggered by photodynamic therapy: when plasma membranes are the main targets J. Cell. Physiol. 194 3 2003 Mar 363 375
43. D.D. Meira, V.H. de Almeida, J.S. Mororo, I. Nobrega, L. Bardella, and R.L. Silva Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells Br. J. Cancer 101 5 2009 Sep 1 782 791
44. D. Miles, M.G. von, and A.D. Seidman Combination versus sequential single-agent therapy in metastatic breast cancer Oncologist 7 Suppl. 6 2002 13 19
45. C.L. Sawyers Cancer: mixing cocktails Nature 449 7165 2007 Oct 25 993 996
46. K. Berg, A. Dietze, O. Kaalhus, and A. Hogset Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin Clin. Cancer Res. 11 23 2005 Dec 1 8476 8485
47. S. Price Putative allosteric MEK1 and MEK2 inhibitors Expert Opin. Ther. Pat. 18 6 2008 603 627
48. G. Bodoky, C. Timcheva, D.R. Spigel, P.J. La Stella, T.E. Ciuleanu, and G. Pover A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest. New Drugs 30 3 2012 Jun 1272 1273
49. J. Rinehart, A.A. Adjei, P.M. Lorusso, D. Waterhouse, J.R. Hecht, and R.B. Natale Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer J. Clin. Oncol. 22 22 2004 Nov 15 4456 4462
50. E.B. Haura, A.D. Ricart, T.G. Larson, P.J. Stella, L. Bazhenova, and V.A. Miller A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin. Cancer Res. 16 8 2010 Apr 15 2450 2457